[
    [
        {
            "time": "2020-06-05",
            "original_text": "Pharma Giant AbbVie Enters Ring With A Potential Coronavirus Treatment",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Coronavirus",
                    "Treatment"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Pharma Giant AbbVie Enters Ring With A Potential Coronavirus Treatment",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-06-05",
            "original_text": "AbbVie Enters the Race to Develop New COVID-19 Treatments",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Race",
                    "COVID-19",
                    "Treatments"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "AbbVie Enters the Race to Develop New COVID-19 Treatments",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-06-05",
            "original_text": "Biotech Stock To Watch: Why This Leader Could Be Poised For Another Run",
            "features": {
                "keywords": [
                    "Biotech",
                    "Stock",
                    "Leader",
                    "Run"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Biotech Stock To Watch: Why This Leader Could Be Poised For Another Run",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2020-06-05",
            "original_text": "The Market Timing Secrets No One Talks About - June 05, 2020",
            "features": {
                "keywords": [
                    "Market",
                    "Timing",
                    "Secrets"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "The Market Timing Secrets No One Talks About - June 05, 2020",
                "Correlation": 2,
                "Sentiment": 5,
                "Importance": 3,
                "Impact": 2,
                "Duration": 3,
                "Entity_Density": 1,
                "Market_Scope": 4,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        },
        {
            "time": "2020-06-05",
            "original_text": "The Zacks Analyst Blog Highlights: AbbVie, Amkor Technology, Calix, The Hain Celestial Group and Acacia Communications",
            "features": {
                "keywords": [
                    "Zacks",
                    "Analyst",
                    "Blog",
                    "AbbVie",
                    "Amkor",
                    "Technology",
                    "Calix",
                    "Hain",
                    "Celestial",
                    "Group",
                    "Acacia",
                    "Communications"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "technology",
                    "healthcare",
                    "communications"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "The Zacks Analyst Blog Highlights: AbbVie, Amkor Technology, Calix, The Hain Celestial Group and Acacia Communications",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2020-06-05",
            "original_text": "Pharma Stock Roundup: LLY Coronavirus Antibody Phase I Study Initiation, FDA Approvals",
            "features": {
                "keywords": [
                    "Pharma",
                    "Stock",
                    "LLY",
                    "Coronavirus",
                    "Antibody",
                    "Phase",
                    "I",
                    "Study",
                    "FDA",
                    "Approvals"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Pharma Stock Roundup: LLY Coronavirus Antibody Phase I Study Initiation, FDA Approvals",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-06-05",
            "original_text": "The Daily Biotech Pulse: Adamas Rallies On FDA Acceptance, Oxford Immunotech Reportedly Gets $400M Bid",
            "features": {
                "keywords": [
                    "Daily",
                    "Biotech",
                    "Pulse",
                    "Adamas",
                    "Rallies",
                    "FDA",
                    "Acceptance",
                    "Oxford",
                    "Immunotech",
                    "Bid"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "The Daily Biotech Pulse: Adamas Rallies On FDA Acceptance, Oxford Immunotech Reportedly Gets $400M Bid",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-06-05",
            "original_text": "AbbVie, Harbour BioMed, Utrecht University and Erasmus Medical Center Announce Collaboration to Develop Monoclonal Antibody Therapy to Prevent and Treat COVID-19",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Harbour",
                    "BioMed",
                    "Utrecht",
                    "University",
                    "Erasmus",
                    "Medical",
                    "Center",
                    "Collaboration",
                    "Monoclonal",
                    "Antibody",
                    "Therapy",
                    "Prevent",
                    "Treat",
                    "COVID-19"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "AbbVie, Harbour BioMed, Utrecht University and Erasmus Medical Center Announce Collaboration to Develop Monoclonal Antibody Therapy to Prevent and Treat COVID-19",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]